Hepatect Cp (Human Hepatitis B Immunoglobulin)

Hepatect Cp is indicated for post‑exposure prophylaxis against hepatitis B virus. It is administered to individuals who have been exposed to hepatitis B through contaminated blood or body fluids.

• Prevention of hepatitis B infection after accidental needle sticks or occupational exposure.
• Post‑exposure prophylaxis for household contacts of hepatitis B carriers.
• Supplementary protection for newborns of hepatitis B‑positive mothers when vaccine alone is insufficient.
• Use in patients with compromised immune response who cannot mount adequate vaccine protection.
• Administration to travelers at high risk of hepatitis B exposure in endemic regions.

Side effects of Hepatect Cp may vary in frequency and severity. Patients should be monitored for any adverse reactions during and after infusion.

Common

• Mild fever or chills during infusion.
• Headache or dizziness.
• Nausea or mild gastrointestinal discomfort.
• Localized redness or swelling at the injection site.

Serious

• Severe allergic reaction (anaphylaxis) with difficulty breathing.
• Acute hemolysis leading to dark urine and fatigue.
• Thrombotic events such as deep vein thrombosis.
• Renal impairment manifested by reduced urine output.
• Severe hypotension or shock during infusion.

Before using Hepatect Cp, healthcare providers should consider several safety factors to minimize risk.

• Verify patient’s hepatitis B serology and vaccination history.
• Assess for known hypersensitivity to human immunoglobulins or any component of the formulation.
• Use caution in patients with a history of cardiovascular disease or fluid overload.
• Monitor renal function, especially in individuals with pre‑existing kidney disease.
• Avoid rapid infusion rates; follow recommended administration guidelines.
• Counsel pregnant or breastfeeding women of unknown safety profile and document risk‑benefit assessment.
• Keep the product refrigerated and protect from light until use.

Hepatect Cp may interact with other medications or clinical conditions. Awareness of potential interactions helps ensure safe administration.

Avoid

• Concurrent use of other blood‑derived products without medical supervision.
• Administration with live vaccines during the same visit.

Use with caution

• Concurrent anticoagulant therapy, as immunoglobulins can affect coagulation parameters.
• Immunosuppressive agents that may alter the patient’s response to passive immunity.
• High‑dose intravenous immunoglobulin therapy for other indications, which may increase risk of renal dysfunction.
• Medications that affect renal clearance, requiring close monitoring of kidney function.